- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
A team from North East England who designed a device which will help monitor gum disease have been awarded more than £1m of UK Government funding.
Biotechnology companies OJ-Bio Ltd and Orla Protein Technologies, together with scientists at Newcastle University, are developing a novel device which has great potential in rapidly detecting the early signs of gum disease and monitoring improvement as the condition is treated. The UK's Technology Strategy Board (TSB) and Engineering and Physical Sciences Research Council (EPSRC) have given the project £1.1m to help develop the prototype into a commercial product.
The project will deliver a device that will enable patients and dentists to monitor gum disease accurately, simply and cost effectively by identifying signs of the disease in saliva.
Gum or periodontal disease is a major healthcare problem in the western world and has been linked with an increased risk of diabetes and other medical problems. It also has a huge economic impact, with an estimated annual cost to the UK economy of £2.78 billion.
The project brings together a multi-disciplinary team of UK excellence in nanoscale science: electronic biosensor company OJ-Bio Ltd, nanobiotechnology company Orla Protein Technologies Ltd and molecular biology and clinical research experts Dr John Taylor and Professor Philip Preshaw, from the Institute of Cellular Medicine (ICM) & Centre for Oral Health Research (COHR) at Newcastle University.
OJ-Bio was created to develop a new generation of hand-held, real-time diagnostic devices that combine biotechnology processes with electronics manufacturing. The company is a joint venture between UK company Orla Protein Technologies and the major electronics company Japan Radio Co. Ltd (JRC).
OJ-Bio had already performed an initial study for the Technology Strategy Board which demonstrated the feasibility of a nanobiosensor device for the detection of proteins called matrix metalloproteinases, which are involved in a variety of diseases. The new project, part of a government-funded programme of business-led nanoscience research and development, will allow the consortium to develop this further into a simple, easy-to-use device for use in real-life situations.
Dr. Dale Athey, CEO of OJ-Bio, said: "This funding is a great boost for the development of our technology in new application areas; it allows us to work with key experts in the field in an area of compelling need. As well as gum disease, we are also developing products to detect respiratory viruses such as flu, and markers of other diseases."
Dr Taylor, principal investigator at Newcastle University, said: "We are delighted to obtain the funding for this project which is an exciting combination of laboratory and clinical investigations. This is an excellent example of translational biomedical research which will deliver new technology for patient benefit, but will also generate important information about the molecular biological processes which underpin chronic inflammatory diseases."
Professor Preshaw, director of the Clinical Research Facility at the Newcastle Dental Hospital, said: "We will test the device in real-life situations - it will be used by dentists, but also by patients. Our objective is to detect gum disease, but also monitor improvement of the condition as we treat it. If we can detect gum disease early, it could save the NHS millions of pounds as well as helping the health of millions of people."
OJ-Bio is a joint venture between Orla Protein Technologies Ltd and Japan Radio Co. Ltd (JRC).
About Orla Protein Technologies
Orla Protein Technologies Ltd is a nano-biotechnology company focused on developing high-performance biosurfaces with applications in cell culture, life science tools, reagents and diagnostics. Orla’s development was supported by investment from NEL Capital and support from the regional development agency, One NorthEast. For more information see www.orlaproteins.com
About Japan Radio Company
Japan Radio Co. Ltd (JRC) is a major Japanese company with global interests in communications and electronics. For more information see http://www.jrc.co.jp/eng/
About the Technology Strategy Board
The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org
For more information, please click here
Dr. Ian Robson
Tel +44 (0) 191 487 5961
Mob +44 (0) 7792 871190
0044 (0) 191 231 3127
Copyright © OJ-BioIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Emergence of a 'devil's staircase' in a spin-valve system July 1st, 2015
Graphene reduces wear of alumina ceramic March 26th, 2015